Merck and ChemLex announced the signing of a Memorandum of Understanding (MOU) to explore a strategic collaboration in evolving R&D paradigms. The MOU reflects a shared commitment to advancing life science and electronics discoveries by combining Merck's deep scientific and translational expertise with ChemLex's automated chemistry platform and data generation capabilities. Together, the parties aim to enhance the speed, efficiency, and reproducibility of chemical research across early discovery and development workflows within Merck's various business sectors. Under the framework of the MOU, Merck and ChemLex intend to explore areas of cooperation that may include automated synthesis, reaction optimization, high-throughput experimentation, and chemistry platform integration.
Initial efforts will focus on identifying high-impact chemistry programs and defining pathways toward potential future collaborations. The signing of the MOU underscores both organizations' interest in scalable, data-rich experimental science and their shared focus on building long-term partnerships that advance innovation at the intersection of chemistry and automation. The parties will continue discussions to evaluate next steps under the MOU framework.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (20%);
- sale of animal health products (9.2%);
- other (1.4%).
Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.